Glenmark: U.S. FDA issues 6 procedural observations at Goa plant

Regulatory & Legal View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹2202.40

prior close

₹2196.40

announcement price

After-mkt

timing

Nifty Midcap 150market+0.2%-2.4% vs market

Pharmaceuticals peers, median of 165sector-0.0%-2.1% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Midcap 150 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.4

15m

-0.7

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1+0.2-2.4-0.0-2.1

Next day

-0.7+0.7-1.4+0.1-0.8

+0.4+0.5-0.1+0.5-0.1

+3.2+0.9+2.3+0.1+3.1

+2.5+0.6+1.9-0.4+2.9

+1.2-1.0+2.2-1.2+2.3

+3.5+1.7+1.8-0.1+3.6

15d

+0.2+0.7-0.5-1.4+1.6

+1.3+2.8-1.6-1.2+2.5

+11.5+2.1+9.4+0.9+10.6

+5.8-5.0+10.8+0.0+5.8

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The U.S. FDA completed a GMP inspection at Glenmark's Goa manufacturing facility from June 22 to June 30, 2026, issuing a Form 483 with six observations. None relate to data integrity, and all are procedural and non-repeat. The company expects no impact on supply of commercial products and will respond to the FDA within the required timeline.

Likely market impact

Form 483 is a routine observation notice. Procedural, non-repeat and non-data-integrity findings are usually manageable, sentiment likely neutral.